Poolbeg Pharma: South Korean patent granted for POLB 001
The patent protects POLB 001 for CRS prevention in South Korea until 2044.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Poolbeg Pharma Granted South Korean Patent for POLB 001
Poolbeg Pharma PLC has announced that a patent relating to its POLB 001 drug has been formally granted in South Korea.